RxDoctor Payments Data

Timothy Baty, DO

Family Medicine · Wynne, ARNPI 1427679133

Payments from drug & device makers

$823in general payments, 2019–2025

Across 31 payments — averaging $26.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$230
  • GSK$168
  • Amgen$131
  • Almatica Pharma LLC$89
  • Otsuka America Pharmaceutical, Inc.$82
  • Cvrx, Inc.$31
  • plus $92 from 5 others

What the payments were for

  • Food & beverage$823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$823 in reported general payments places this provider in the 55th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$40,241
Medicare patients
174
Services billed
607

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$44,226
OzempicSemaglutide42$36,956
JardianceEmpagliflozin40$31,293
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$9,041
Breo ElliptaFluticasone/Vilanterol17$6,122
Novolog FlexpenInsulin Aspart11$2,540
Gabapentin85$2,127
Ventolin HfaAlbuterol Sulfate23$1,877
Albuterol Sulfate HfaAlbuterol Sulfate61$1,707
Potassium Chloride100$1,322
Atorvastatin Calcium202$1,250
Amlodipine Besylate183$1,192
Celecoxib42$1,020
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen84$900
Fluticasone Propionate88$860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$17$44,22653 claims
Novo NordiskOzempic$28$36,95642 claims
GSKTrelegy Ellipta, Breo Ellipta$168$15,16430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Wynne

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →